Epinephrine Auto-Injectors Market Forecast 2022 to 2032 | By End-User, Dosage, Age Group & Region

The Epinephrine Auto-Injectors Market Sales is expected to expand to US$ 3.2 billion by 2032, up from US$ 2 billion in 2022, with a compound annual growth rate (CAGR) of 4.9% between 2022 and 2032.

The market for Epinephrine Auto-Injectors is predicted to increase steadily in the coming years. This is owing to major advances in syringes and injectors in response to changing clinical and patient needs, which has resulted in increased demand for Epinephrine Auto-Injectors.

The potential in the market for Epinephrine Auto-Injectors are rapidly expanding. The rising prevalence of allergies among people has been a primary driver of market expansion. The growing number of people who are allergic to dust, insect bites and venom, food, and food additives has fueled the rise of the epinephrine auto-injector industry.

Furthermore, vendor investments in R&D endeavours to produce chlorofluorocarbon-free epinephrine auto-injector inhalers that use hydrofluoroalkanes as propellants have accelerated the major trends and opportunities in the Epinephrine Auto-Injectors market.

For Details on Vendors and Their Offerings – Request A Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-14876

Excessive epinephrine use, on the other hand, can cause serious side effects such as cardiac arrhythmia, pulmonary edoema, vomiting, and brain haemorrhage, which may represent a threat to the epinephrine auto-injector business.

The increasing number of people suffering from various types of allergies, the availability of low-cost generic Epinephrine Auto-Injectors, and the high adoption rate of Epinephrine Auto-Injectors in the United States are expected to drive the regional market for Epinephrine Auto-Injectors during the forecast period. The epinephrine auto-injector market’s adoption patterns are also predicted to help to its growth.

Key takeaways:

• The Epinephrine Auto-Injectors market in the United States is expected to reach US$ 1.2 billion by 2032, growing at a CAGR of 4.7% through 2032.
• The market for Epinephrine Auto-Injectors in the United Kingdom is estimated to be worth US$ 132.9 million by 2032, with a CAGR of 3.6% from 2016 to 2032.
• China’s market share for Epinephrine Auto-Injectors is estimated to reach US$ 233.7 million by 2032, with a CAGR of 4.2% through 2032.
• In Japan, the market for Epinephrine Auto-Injectors is estimated to be worth US$ 188.5 million by 2032, growing at a 3.3% annual pace until then.
• South Korea is predicted to reach a market size of US$ 117.6 million in Epinephrine Auto-Injectors by 2032, with a CAGR of 2.8% between now and then.
• The Epinephrine Auto-Injectors market’s Hospitals segment from the end user category is predicted to develop at a CAGR of 4.8% through 2032.
• Through 2032, 0.3 mg sector in the Epinephrine Auto-Injectors market’s dosage category will grow at a CAGR of 4.9%.

Ask More About This Market’s Geographical Distribution Along With a Detailed Analysis of the Top Regions@ https://www.futuremarketinsights.com/ask-question/rep-gb-14876

Competitive landscape:

New market research report on Epinephrine Auto-Injectors says that Adamis Pharmaceuticals Corporation, Alk-Abello A/S, Impax Laboratories, Inc., Mylan N.V., Antares Pharma is among the legacy player’s vendors.

The research offers a comprehensive competition analysis of these top competitors in the Epinephrine Auto-Injectors market, including Epinephrine Auto-Injectors market growth, Epinephrine Auto-Injectors market share, Epinephrine Auto-Injectors market adoption trends and important market strategies.

Recent Development in the Epinephrine Auto-Injectors:

• In August 2020, Antares Pharma (US) reached an agreement with Lunatus Global Medical Supplies. (Dubai). Under this agreement, Antares will send packaged goods to Lunatus, and Lunatus will submit and obtain regulatory approval for XYOSTED in the UAE and Saudi Arabia, as well as promote, market, and sell XYOSTED in these two countries.
• In March 2020, SHL Medical (Switzerland) acquired Weibel CDS. (Switzerland). The purpose of this acquisition was to strengthen SHL Medical’s ability to develop more sophisticated medicine delivery systems based on human-centered designs and functionality.
• In January 2020, Eli Lilly invested $470 million and created around 460 new jobs in Durham, North Carolina. With this expansion, North Carolina’s research triangle park got a new cutting-edge pharmaceutical manufacturing facility.

Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/14876

Key Segments:

By End-User:

• Hospitals
• Clinics
• Home Based
• Others

By Dosage:

• 0.15 mg
• 0.3 mg
• Others

By Age Group:

• 0-4 Years
• 5-14 Years
• 15-24 Years
• 25-49 Years
• 50-64 Years
• Above 65 Years

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs